feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Jaguars overwhelm Jets 48-20

trending

Mbappe scores against Alaves

trending

Trevor Lawrence shines, 5 TDs

trending

Patriots Bills Week 15 Game

trending

NFL playoff picture Week 15

trending

Rams extend Puka Nacua contract

trending

NHL threatens 2026 Olympics

trending

Nick Reiner killed his parents

trending

Snow causes school delays

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Psychedelic Therapy Provides Solace for Terminally Ill Patients

Psychedelic Therapy Provides Solace for Terminally Ill Patients

15 Nov

•

Summary

  • Psychedelic therapy helps terminally ill patients cope with depression, anxiety, and fear of death
  • UK lags behind other countries in allowing access to psychedelic research and treatments
  • Public support for relaxing restrictions on psilocybin research, especially for terminal illness
Psychedelic Therapy Provides Solace for Terminally Ill Patients

As of November 15th, 2025, a growing body of evidence suggests that psychedelic therapy could offer significant benefits for terminally ill patients struggling with the emotional and existential challenges of dying. In landmark studies, a high dose of psilocybin combined with psychological support has been shown to rapidly reduce depression and anxiety in cancer patients, with effects lasting up to six months.

Many participants in these studies have reported experiences of deep emotional release, a sense of awe, and a newfound connection that helped them reframe their relationship to death. This contrasts with the limited success of standard treatments like antidepressants and counseling in helping patients fully accept their diagnosis or find meaning in their remaining time.

Despite the promising clinical data and growing public support for relaxing restrictions on psilocybin research, especially for those with terminal illnesses, the UK continues to lag behind other countries in embracing this approach. Psychedelics are tightly controlled in the UK, making research and access to these treatments nearly impossible. This stands in stark contrast to the regulatory shifts seen in places like Australia, Germany, and Canada, which are beginning to allow access to psychedelics for people with serious or treatment-resistant conditions.

As the UK's end-of-life bill is currently being debated in parliament, the potential role of psychedelic therapy in supporting those facing the emotional and existential challenges of dying has become a topic of renewed public interest. The bill's focus on legalizing assisted dying has sparked a broader conversation about the quality and scope of end-of-life care, highlighting the limits of conventional approaches to psychological suffering.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Psychedelic therapy involves the use of substances like psilocybin in combination with psychological support to help patients explore difficult emotions, shift perspective, and achieve profound psychological breakthroughs. Studies have shown it can reduce depression and anxiety in terminally ill cancer patients.
The UK continues to classify psychedelics as substances of little or no medicinal value, making research and access to these treatments nearly impossible. This is in contrast to countries like Australia, Germany, and Canada, which are beginning to allow access to psychedelics for people with serious or treatment-resistant conditions.
The end-of-life bill currently being debated in the UK parliament has sparked a broader conversation about the quality and scope of end-of-life care, highlighting the limits of conventional approaches to psychological suffering. This has led to renewed public interest in the potential role of psychedelic therapy in supporting those facing the emotional and existential challenges of dying.

Read more news on

Healthside-arrowAustraliaside-arrowGermanyside-arrow

You may also like

Child Deaths Surge as Aid Cuts Bite

4 Dec • 107 reads

Billionaire Heirs Inherit Record Wealth in 2025

4 Dec • 69 reads

article image

Culture Clash: Why Australians Hate Agents, Americans Don't

2 Dec • 78 reads

article image

England's Pink Ball Woes Continue

28 Nov • 111 reads

article image

Canada Greenlights Unlabeled Cloned Meat Sales, Angering Americans

14 Nov • 123 reads

article image